Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax (TUD-RELAX1-070) Ended

2024-514018-12-00 female and male adult patients with acute myeloid leuke 9 2020-04-06
A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi… Ended

2023-507276-53-00 Myelofibrosis 4 2020-03-23
Study that evaluating the efficacy of lenvatinib in patients with locally advanced GIST after failure of imatinib and sunitinib Ended

2024-513984-22-00 Patients with metastatic GIST 4 2020-03-17
A Study to Evaluate Safety and Anti-Tumor Activity of RO7284755 Alone or in Combination with Atezolizumab in Participants with Advanced and/… Ended

2023-503749-76-00 Solid Tumors 1 2020-03-06
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Metastatic non-clear cell renal cell carcinoma 4 2020-03-06
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001) Ended

2023-509542-35-00 Advanced Pancreatic cancer, Unresectable Glioblastoma a 3 2020-03-02
CONGRATS : COMBINATION OF NIVOLUMAB PLUS RELATLIMAB IN PATIENTS WITH ADVANCED OR METASTATIC SOFT-TISSUE SARCOMA: A PROOF-OF-CONCEPT RANDOMIZ… Ended

2023-509495-42-00 Adult participants with advanced unresectable or metast 4 2020-02-27
A Study to evaluate the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously … Ended

2023-507389-15-00 Advanced Melanoma 4 2020-02-26
Inhibition of AKT in combination with antibodies targeting the protein HER2 in patients with advanced or metastatic breast cancer and with a… Ended

2023-508826-92-00 Patients with PIK3CA-mutant, HER2-positive locally adva 3 2020-02-14
Efficacy and safety of Cabozantinib in patients with hepatocellular carcinoma progressing on or intolerant to prior treatment with immune ch… Ended

2024-516972-14-00 Hepatocellular carcinoma 4 2020-01-30
A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents Ended

2023-507904-30-00 solid tumors 3 2020-01-27
Olaparib Plus Pembrolizumab Compared to Chemotherapy Plus Pembrolizumab After Initial Treatment With Chemotherapy Plus Pembrolizumab in Trip… Ended

2022-500418-24-00 Locally Recurrent Inoperable or Metastatic Triple Negat 10 2020-01-17
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in … Ended

2023-508993-27-00 Chronic myelogenous leukemia 4 2020-01-17
A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary… Ended

2024-517065-16-00 Melanoma 4 2020-01-13
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLC Ended

2024-517429-24-00 Non-small-cell lung cancer 7 2020-01-09
REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer Ended

2023-506248-18-00 MET-altered non-small cell lung cancer (NSCLC) 7 2020-01-07
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Breast cancer patients including those with locally adv 4 2019-12-09
A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations Ended

2023-510301-18-00 Advanced solid tumors (other than Urothelial tumors), a 4 2019-12-05
CIRCULATE Ended

2023-506715-18-00 colon cancer stage II, rectal cancer stage II 5 2019-12-04
Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinant… Ended

2024-513074-22-00 non-small cell lung cancer (NSCLC) of clinical stages I 4 2019-12-02
A Study Evaluating the Safety and Efficacy of Polatuzumab Vedotin in Combination with Rituximab Plus Gemcitabine Plus Oxaliplatin (R- GEMOX)… Ended

2024-512537-33-00 Relapsed/refractory diffuse large B-cell lymphoma (DLBC 5 2019-11-28
A study of nivolumab and ipilimumab in untreated patients with stage 3 NSCLC that is unable or not planned to be removed by surgery Ended

2022-502886-71-00 Previously Untreated Locally Advanced Non-small Cell Lu 5 2019-11-20
Tepotinib plus osimertinib in osimertinib-relapsed MET amplified NSCLC Ended

2024-512005-87-00 Lung Cancer 4 2019-11-07
Treatment with Acalabrutinib in patients with chronic lymphocytic leukemia Ended

2023-507669-24-00 Chronic lymphocytic leukemia 5 2019-11-05